Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05362968Phase 1Completed
Phase 1, randomised, open-label trial in prediabetes and metabolic syndrome (2 arms), sponsored by University of Nevada, Las Vegas. Primary endpoints: Glycemic control at 12 weeks and Lipid control at 12 weeks. Started Jan 2023; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05362968.